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The mitogen-activated protein kinase (MAPK) pathway is frequently aberrantly activated in
advanced cancers, including metastatic prostate cancer (CaP). However, activating mutations
or gene rearrangements among MAPK signaling components, such as Ras and Raf, are not
always observed in cancers with hyperactivated MAPK. The mechanisms underlying MAPK
activation in these cancers remain largely elusive. Here we discover that genomic amplifi-
cation of the PPP1CA gene is highly enriched in metastatic human CaP. We further identify an
S6K/PP1α/B-Raf signaling pathway leading to activation of MAPK signaling that is antag-
onized by the PML tumor suppressor. Mechanistically, we find that PP1α acts as a B-Raf
activating phosphatase and that PML suppresses MAPK activation by sequestering PP1α into
PML nuclear bodies, hence repressing S6K-dependent PP1α phosphorylation, 14-3-3 binding
and cytoplasmic accumulation. Our findings therefore reveal a PP1α/PML molecular network
that is genetically altered in human cancer towards aberrant MAPK activation, with important
therapeutic implications.
DOI: 10.1038/s41467-017-02272-y OPEN
1 Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, MA 02215, USA. 2Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115,
USA. 3 Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. 4 School of Biological Sciences, The
University of Hong Kong, Hong Kong 999077, China. Correspondence and requests for materials should be addressed to
P.P.P. (email: ppandolf@bidmc.harvard.edu)
NATURE COMMUNICATIONS |  (2018) 9:159 |DOI: 10.1038/s41467-017-02272-y |www.nature.com/naturecommunications 1
12
34
56
78
9
0
Activation of signaling pathways, such as thephosphoinositide-3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK), is regulated by feed-
back inhibition in both normal and cancer cells1,2. Evasion of
feedback inhibition or failsafe mechanisms resulting from aber-
rant activation of major oncogenic pathways represent one of the
critical mechanisms underlying tumor progression in tumors of
diverse histological origin3,4. On the other hand, relief of negative
feedback by anticancer drugs constitutes a major hurdle to limit
the success of several targeted therapies5. Hence, identification of
the key pathways that govern such regulation is of utmost
importance for tumor-specific therapeutic targets.
Prostate cancer (CaP) is the most common malignancy found
in men, and an estimated 1 in 7 men in the United States will be
diagnosed with CaP during their lifetime6. In the past 25 years,
CaP mortality has declined by nearly 40%; however, improve-
ment in survival for patients with metastatic disease has not
contributed substantially to the observed drop in CaP mortality7.
More than 26,000 men in the United States die annually of
metastatic CaP6. Recent whole-exome sequencing studies have
revealed that copy number alterations, recurrent somatic muta-
tions and genomic rearrangements are among the driving forces
for metastatic castration-resistant prostate cancer (mCRPC) and
have identified distinct molecular subtypes of mCRPC based on
alterations in existing signaling pathways8,9.
Co-activation of the PI3K/AKT and MAPK pathways is fre-
quently observed in advanced and metastatic CaP and is found to
be associated with disease progression and poor prognosis10. One
of the dominant mechanisms underlying PI3K/AKT activation is
inactivation of PTEN (phosphatase and tensin homolog)11. In
contrast, the mechanisms underlying MAPK activation, to date,
remain largely elusive since activating mutations or gene rear-
rangements among MAPK signaling components are rare in
human CaP8,12–17. Notably, PTEN loss/PI3K–AKT activation
occurs as an early event in the development of human CaP18,
leading to feedback inhibition on Ras/Raf/MAPK signaling19,20
(Supplementary Fig. 1a-b). How human CaP evades this feedback
inhibition to frequently co-activate the PI3K/AKT and MAPK
signaling is also poorly understood. In view of these critical gaps
in the field, we investigated the mechanistic basis of MAPK
activation in metastatic human CaP.
Here we report an S6K/PP1α/B-Raf pathway that activates
MAPK signaling in PI3K/AKT-driven cancers and is opposed by
the promyelocytic leukemia (PML) tumor suppressor. We further
demonstrate its importance in regulating CaP cell migration and
invasion and in metastatic human CaP.
Results
Amplification of PPP1CA in metastatic human CaP. It is now
well recognized that the MAPK cascade is negatively regulated
through inhibitory phosphorylation of components of the path-
way, in particular, Raf kinases, the major upstream activators of
MAPK signaling21–25. Raf kinases can not only be switched on by
acquiring activating mutations, but also through phosphatase-
mediated dephosphorylation at their inhibitory sites to relieve
inhibition and to allow reactivation21,22,26,27. Given that activat-
ing mutations in Raf kinases are rare in human CaP, we postu-
lated that aberrant phosphatase activity might promote Raf
kinases activity and subsequent MAPK activation in metastatic
human CaP.
We focused on PP2A and PP1, two major eukaryotic protein
phosphatases that are reported to contribute to >90% of serine/
threonine dephosphorylation and regulate a variety of cellular
processes through the dephosphorylation of distinct substrates28,
and we initially sought to determine if genetic alterations to either
of these protein phosphatases could help establish a role in the
context of metastatic cancer. Interestingly, the catalytic subunit of
protein phosphatase 1α (PP1α), encoded by the PPP1CA gene in
humans, is located on chromosomal band 11q13, one of the
regions frequently amplified in comparative genomic hybridiza-
tion (CGH) analysis of human CaP29,30. Moreover, enhanced
cytoplasmic PP1α immunostaining strongly correlates with high
Gleason Score30, suggesting that PP1α may be involved in
prostate tumorigenesis. To confirm the relevance of PPP1CA to
human CaP, we evaluated the genomic status of PPP1CA in a
recent array-based CGH (aCGH) data set8 of 59 localized prostate
cancer (LPC) and 35 mCRPC CaP. We found that PPP1CA was
amplified in 7% of LPC and 17% of mCRPC, respectively
(Fig. 1a). To independently validate the findings from the aCGH
data set, we analyzed a recent large whole-exome sequencing data
set9 of 150 samples from mCRPC patients. Consistent with the
aCGH analysis, PPP1CA was amplified in 25% of mCRPC
(Fig. 1b). Notably, PPP1CA, which is ~2Mb away from cyclin D1
a proto-oncogene also associated with metastatic CaP18, was
more frequently amplified than cyclin D1 in mCRPC (25% vs 5%,
Fig. 1c). Also of interest, PPP1CA was co-amplified with cyclin
D1 in 5 out of 7 cases where the latter was amplified (Fig. 1c).
Thus, amplification of PPP1CA occurs frequently in metastatic
human CaP.
PP1α mediates PML-loss-induced MAPK activation. We pre-
viously reported that co-deletion of PTEN and PML leads to
MAPK reactivation in mouse prostate epithelial cells and human
CaP cells and frequently occurs in metastatic human CaP31 To
determine if PPP1CA genomic amplification could cooperate with
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Fig. 1 Amplification of PPP1CA occurs frequently in metastatic human CaP
and is often mutually exclusive with co-deletion of PTEN and PML. a, b Bar
graph showing the percentage of amplification of PPP1CA in LPC and
mCRPC samples from the Grasso et al.8 data set (a) and in mCRPC
samples from the Robinson et al.9 data set (b). c Bar graph showing the
percentage of amplification of cyclin D1 alone or together with PPP1CA in
mCRPC samples from the Robinson et al.9 data set. d Association between
genomic amplification of PPP1CA and co-deletion of PTEN and PML from the
Robinson et al.9 data set. Data were analyzed by Fisher’s exact test, P<
0.05 was considered significant
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co-deletion of PTEN and PML in metastatic human CaP, we
determined whether amplification of PPP1CA was correlated with
co-deletion of PTEN and PML in the Robinson et al.9 data set.
Strikingly, we found that PPP1CA genomic amplification and co-
deletion of PTEN and PML were often mutually exclusive
(Fig. 1d), supporting their proto-oncogenic functions in the same
pathway. In keeping with this notion, overexpression of PP1α
induced a marked increase in extracellular signal regulated kinase
(ERK) phosphorylation (Fig. 2a and Supplementary Fig. 2a).
Conversely, knockdown of PP1α via small interfering RNA
(siRNA) attenuated ERK phosphorylation in both LNCaP and
PC3 cells (Fig. 2b), suggesting that PP1α is the principle phos-
phatase that positively regulates the MAPK signaling pathway. In
contrast, although PP2A has previously been identified as the
phosphatase mediating the dephosphorylation and reactivation of
Raf kinases (Supplementary Fig. 2b)22, the overexpression or
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Fig. 2 PP1α mediates PML-loss-induced MAPK activation. a, b Immunoblot (IB) analysis of lysates from 293T cells transfected with empty vector (EV) or
Flag-PP1α for the indicated times (a), lysates from LNCaP or PC3 cells transfected with control or PP1α siRNA for 48 h (b). c, d Immunofluorescence (c)
and fractionation (d) of PP1α protein in WI-38 cells transfected with control, PTEN or PTEN plus PML siRNA for 48 h. Quantification of the percentage of
PP1α protein in the cytosolic and nuclear fraction was carried out with ImageJ software after it was normalized against cytosolic marker HSP90 and nuclear
marker Lamin B1, respectively. Data shown are mean± s.e.m. of three independent experiments. Scale bar, 5 μm. e Immunofluorescence and IB analysis of
293T cells transfected with EV, WT or NLS-tagged Flag-PP1α. Scale bar, 5 μm. f Endogenous reciprocal co-immunoprecipitation of PML and PP1α in PC3
cells. Input is 10% of total cell extracts used for immunoprecipitation. *Indicates a nonspecific band. g IB analysis of lysates from control or PML stable
knocked-down PC3 cells transfected with control or PP1α siRNA for 48 h, followed by serum-starvation for 4 h and stimulation with 10 ng/ml EGF for 5 min.
Quantification of p-ERK/ERK levels was carried out with ImageJ software. Numbers indicate the relative ratios to controls for phosphoprotein/total protein.
Data shown are mean± s.e.m. of three independent experiments. h IB analysis of lysates from 293T cells transfected with EV, WT or phosphatase-inactive
(H248K) Flag-PP1α for 24 h
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silencing of the PP2A catalytic subunit (PP2A-C) did not affect
ERK phosphorylation in either 293T cells or CaP cell lines
(Supplementary Fig. 2c-e), presumably due to its complex effects
on various components of the MAPK cascade32, and no con-
sistent genomic alterations in PPP2CA, the gene encoding
PP2A-C protein, have been found in mCRPC samples from the
Robinson et al.9 data set (Supplementary Fig. 2f).
Although co-deletion of PTEN and PML is often mutually
exclusive with amplification of PPP1CA, we did not rule out the
possibility that co-loss of PTEN/PML might lead to aberrant PP1α
phosphatase activity, thereby contributing to PML-loss-induced
MAPK activation. It is well established that PML is induced
upon PTEN inactivation in a p53-dependent and -independent
manner4,33,34 and that PML, through its nuclear body (NB)-
dependent scaffold activity, can interact with a variety of proteins,
including phosphatases, to regulate their functions35. Additionally,
PP1α is a known Rb phosphatase and, like PML, can bind Rb
(Supplementary Fig. 2g) and cooperate with Rb function in the
induction of cellular senescence36. We therefore considered that
upon PTEN loss, PML might recruit PP1α into the PML-NBs to
promote PTEN-loss-induced cellular senescence, a potent failsafe
mechanism that restricts tumorigenesis4, and simultaneously
restrict PP1α-induced MAPK activation. WI-38 human diploid
fibroblasts, the well-accepted cell model used to study the
senescence with intact PTEN and PML protein expression, were
used to test this possibility. We found that acute knockdown of
PTEN in WI-38 cells induced senescence, PML upregulation,
strong co-localization of PML and PP1α, and suppression of
MAPK signaling (Supplementary Fig. 2h and Fig. 2c, d). On the
other hand, we reasoned that in PTEN/PML double-null cells, due
to the lack of sequestration to NBs, PP1α could contribute to
MAPK activation through the dephosphorylation and reactivation
of Raf kinases. In support of this hypothesis, the cytoplasmic
accumulation of PP1α was significantly increased upon simulta-
neous knockdown of PTEN and PML along with concomitant
MAPK reactivation in WI-38 cells (Fig. 2c, d). Moreover,
compared to wild-type (WT) PP1α, a PP1α mutant constitutively
targeted to the nucleus by fusing the NLS sequence derived from c-
Myc37 displayed a drastically decreased capacity to activate ERK
(Fig. 2e), further corroborating the role of subcellular compart-
mentalization in the regulation of PP1α-induced ERK activation.
Importantly, PML and PP1α interacted with each other in vivo in
PTEN-null CaP cells. Immunoprecipitation of PML led to the co-
immunoprecipitation of PP1α and vice versa in PC3 cells (Fig. 2f).
To further investigate whether PP1α might mediate PML-loss-
driven MAPK activation, we used siRNA targeting PP1α in stable
PML knockdown cells. We found that the induction of basal and
EGF-stimulated ERK phosphorylation through stable knockdown
of PML was suppressed by PP1α downregulation (Fig. 2g).
Therefore, PML-loss-driven MAPK activation is mediated, at
least in part, by PP1α. Notably, the phosphatase activity of PP1α
is required for MAPK activation since expression of the
phosphatase-inactive PP1α mutant (H248K)38 did not affect
ERK phosphorylation (Fig. 2h). In line with this, PC3 cells treated
with tautomycin, a more selective inhibitor for PP1α39–42,
displayed a dose-dependent inhibition of EGF-induced ERK
phosphorylation (Supplementary Fig. 2i). Thus, we conclude that
in PTEN and PML double-null cells, sequestration of PP1α to
NBs is impaired and in turn facilitates the aberrant cytosolic
localization of PP1α and its subsequent activation of MAPK
signaling.
S6K induces PP1α phosphorylation, 14-3-3 binding and cyto-
plasmic accumulation. To gain further mechanistic insights into
how PP1α is delocalized into the cytoplasm, we examined which
AGC kinase can trigger cytoplasmic accumulation of PP1α given
that the AGC family kinases are commonly activated upon PTEN
loss43. We found that S6K1, but not other AGC kinases such as
AKT and SGK, phosphorylated PP1α in vivo (Fig. 3a), induced
the interaction of PP1α with 14-3-3γ (Fig. 3b) and led to
increased cytoplasmic accumulation of PP1α (Fig. 3c, d). Notably,
knockdown of S6K1 via siRNA largely suppressed PP1α-induced
ERK activation (Fig. 3e), suggesting that activation of ERK by
PP1α is dependent on S6K. In support of PP1α being an S6K
substrate, we identified two highly conserved imperfect AGC
family kinase-recognition motifs (RxRxxpS/T) located at S224/
T226 and T320 of PP1α protein, respectively (Fig. 3f). We gen-
erated PP1α mutants in which S224/T226 (S224A/T226A), T320
(T320A) or all three sites (3A) were mutated to alanine. In vitro
kinase assays confirmed that recombinant S6K1 could also
phosphorylate PP1α (Fig. 3g). Moreover, S224A/T226A and 3A
PP1α mutants, but not T320A, displayed drastically reduced
S6K1-dependent PP1α phosphorylation (Fig. 3g). Consequently,
S224A/T226A and 3A PP1α mutants had a lower capacity to
interact with 14-3-3 and to activate MAPK signaling (Fig. 3h, i),
suggesting that S6K-mediated PP1α phosphorylation on S224/
T226 is critical for the binding of PP1α with 14-3-3 and for the
ability of PP1α to activate MAPK.
PP1α dephosphorylates B-Raf inhibitory phosphorylation
sites. Next, we asked if PP1α could interact with Raf family
kinases. Immunoprecipitation of PP1α revealed a strong and
specific interaction between PP1α and B-Raf and to a lesser
extent, A-Raf, while PP1α did not interact with C-Raf or other
components of the MAPK cascade, such as MEK and ERK
(Fig. 4a, the left panel). Given that A-Raf shows weak interaction
with PP1α and has low intrinsic activity towards MAPK activa-
tion44, further studies investigating the effect of PP1α on Raf
family kinases were focused on B-Raf. The interaction between
PP1α and B-Raf was further confirmed by reciprocal immuno-
precipitation in which PP1α co-immunoprecipitated with anti-B-
Raf precipitates (Fig. 4a, the right panel).
The observation that PP1α and B-Raf interact and that the
phosphatase activity of PP1α is required for MAPK activation led
us to investigate whether B-Raf might be a putative substrate of
PP1α. We therefore asked if B-Raf itself is dephosphorylated by
PP1α. Since ERK-mediated feedback inhibitory phosphorylation
on S151, T401, S750 and T753 of B-Raf protein negatively
regulates its kinase activity22, we reasoned that PP1α could
dephosphorylate these inhibitory sites and, in turn, relieve
feedback inhibition and reactivate MAPK. To address whether
PP1α activates B-Raf through these inhibitory sites, we made use
of B-Raf protein mutants in which an individual inhibitory site, as
well as all four sites (4A), were mutated to alanine. As expected,
cells overexpressing either PP1α or WT B-Raf had higher ERK
phosphorylation than cells transfected with empty vector (Fig. 4b).
Additionally, cells overexpressing both PP1α and WT B-Raf
displayed even higher ERK phosphorylation (Fig. 4b), suggesting
that PP1α can enhance B-Raf activity. On the other hand, the 4A
B-Raf mutant, but not single alanine B-Raf mutants, displayed an
enhanced basal ability to activate MAPK compared to WT B-Raf
(Fig. 4b), indicating that these four sites indeed negatively
regulate B-Raf activity, while dephosphorylation of a single
inhibitory site is not sufficient to increase B-Raf activity.
Critically, the 4A B-Raf mutant was insensitive to PP1α activation
(Fig. 4b). In contrast, mutation of other known B-Raf inhibitory
phosphorylation sites, including S365A/S429A/T440A24, S465A/
S467A25 and S614A23, to alanine failed to blunt PP1α-mediated
ERK activation (Supplementary Fig. 2j-l). Therefore, PP1α
appears to exert its effect on B-Raf primarily through the ERK-
regulated inhibitory sites.
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To determine which site could be dephosphorylated by PP1α,
we purified GST-3A-B-Raf proteins in which one inhibitory
site was WT and the other three sites were mutated to alanine.
GST-WT-B-Raf and GST-4A-B-Raf protein were included as the
positive and negative control, respectively. We then phosphorylated
GST-B-Raf in vitro by incubating B-Raf with recombinant ERK2
protein, and next used the phosphorylated form of B-Raf as a
substrate for recombinant PP1α. We confirmed that GST-B-Raf
was phosphorylated by ERK2 in vitro22, mainly on S151 and T753
(Fig. 4c), and found that PP1α dephosphorylated B-Raf on both
ERK phosphorylation sites (Fig. 4d). Thus, PP1α appears to
dephosphorylate these inhibitory sites of B-Raf, triggering relief of
feedback inhibition and consequent activation of the MAPK
pathway.
PP1α promotes CaP cell invasiveness via MAPK signaling. The
identification of PPP1CA amplification in metastatic human CaP
is consistent with a pro-metastatic role for PPP1CA in the pros-
tate (Fig. 1a, b). We therefore examined whether overexpression
of PP1α affects CaP cell migration and invasion. Indeed, we
found that LNCaP cells stably overexpressing PP1α exhibited
higher ERK activation along with significantly increased cell
migration and invasion (Fig. 4e). Notably, treatment with the
MEK inhibitor, U0126, in LNCaP cells repressed not only basal
but also PP1α-induced cell migration and invasion (Fig. 4e).
Similar results were also obtained in PC3 cells (Supplementary
Fig. 2m). These functional data, together with the human genetic
and mechanistic analyses, implicate PPP1CA as a pro-metastatic
proto-oncogene in human CaP and MAPK signaling as one of the
key downstream effectors of PP1α-induced cell invasiveness.
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Discussion
Integrated genetic and molecular analyses allowed us to identify
an S6K/PP1α/B-Raf pathway towards the aberrant activation of
MAPK signaling. We find that this pathway is suppressed by the
PML tumor suppressor through sequestration of PP1α into NBs
in PTEN-null cells as a result of failsafe mechanisms evoked by
PTEN loss (Fig. 4f). Although the critical role of PP1- and PP2A-
mediated dephosphorylation in the activation of Raf kinases has
previously been reported26,27,45,46, we show here for the first time
that (1) PP1α is amplified in metastatic human CaP and is the
principle phosphatase positively regulating MAPK activation and
that (2) S6K-mediated PP1α cytoplasmic accumulation is essen-
tial for the activation of MAPK by PP1α. Importantly, given that
PML is frequently lost in human cancer47, our study suggests that
aberrant cytoplasmic retention of PP1α caused by PML loss or the
amplification of PPP1CA might represent a common mechanism
underlying MAPK activation in cancers that lack activating
mutations or gene rearrangements among MAPK signaling
components, such as breast cancer and CaP13–17,48,49. Notably,
since nuclear PP1α has been shown to activate Rb tumor sup-
pressor through dephosphorylation50, PML and PML-NBs do
serve as rheostats to switch PP1α activity from tumor suppressive
to tumor promoting. It is also worth noting that although both
PML and 14-3-3γ interact with PP1α, neither of them affect PP1α
phosphatase activity towards dephosphorylating its respective
nuclear and cytosol substrates (Supplementary Fig. 2n,o), sug-
gesting that PML or 14-3-3γ primarily functions as a scaffold/
chaperone for PP1α rather than as a direct regulator of PP1α
phosphatase activity.
Additionally, as S6K is a downstream target of the ERK
pathway51,52, our study suggests that in the context of PML loss
or PPP1CA amplification, the S6K/PP1α/B-Raf/ERK pathway
represents a feed-forward loop supporting sustained ERK acti-
vation. However, we and others have previously also shown that
AKT/mTOR/S6K activation triggers a negative feedback on
MAPK signaling pathway, presumably as a result of the upstream
IRS inactivation induced by S6K19,53 (Supplementary Fig. 1).
Thus, depending on the genetic context, S6K is a double-edge
sword in the regulation of ERK activation, since it can act as both
a suppressor of ERK activation, in the context of intact PML
function, and as a promoter of sustained ERK activation, in the
context of PML loss or PPP1CA amplification.
Collectively, our findings have important implications for
tumorigenesis at large because simultaneous activation of MAPK
and PI3K/AKT signaling undoubtedly represents a devastating
force in propelling cancers into more advanced and aggressive
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Fig. 4 PP1α acts as a B-Raf activating phosphatase and promotes CaP cell invasiveness through activation of MAPK signaling. a Endogenous co-
immunoprecipitation of PP1α with A-Raf, B-Raf, C-Raf, MEK and ERK (the left panel) or B-Raf with PP1α (the right panel) in PC3 cells. Input is 10% of total
cell extracts used for immunoprecipitation. *Indicates a nonspecific band. b IB analysis of lysates from 293T cells transfected with the indicated WT or
mutant Flag-B-Raf constructs plus EV or Flag-PP1α for 24 h. Quantification of p-ERK/ERK levels was carried out with ImageJ software. Numbers indicate
the relative ratios to controls for phosphoprotein/total protein. Data shown are mean± s.e.m. of three independent experiments. c In vitro ERK-mediated B-
Raf kinase assays. Bacterial-expressed WT or mutant GST-B-Raf was purified and incubated with ERK2 in the kinase buffer with [γ-32P] ATP. Reaction was
stopped by sample buffer and resolved by SDS-page. d In vitro ERK-mediated B-Raf kinase and PP1α phosphatase assay. Bacterial-expressed WT or mutant
GST-B-Raf was purified and incubated with ERK2 in the kinase buffer with [γ-32P] ATP in the absence or presence of recombinant PP1α. Reaction was
stopped by sample buffer and resolved by SDS-PAGE. e Representative images and quantitation of migrated and invaded LNCaP cells in the migration and
invasion assay. LNCaP stable cells were subjected to migration (24 h) or invasion assay (48 h) in the absence or presence of 20 μM U0126. IB analysis
confirmed the expression of phosphor-ERK and PP1α. Data shown are mean± s.e.m. of three independent experiments. **P< 0.01, ***P< 0.001 by
unpaired two-tailed t-test. Scale bar, 100 μm. f A model of the regulation of MAPK activation in PTEN-null cells by S6K, PP1α, B-Raf and PML
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diseases. Since MAPK activity can be suppressed/inhibited by
small pharmacological inhibitors, this study provides a compel-
ling rationale for investigating whether patients with co-deletion
of PTEN and PML or amplification of PPP1CA may benefit sig-
nificantly from combinatorial therapy targeting both AKT/mTOR
and MAPK signaling that is worthy of further investigations.
Methods
Plasmids, reagents and antibodies. Human WT and c-terminal NLSc-Myc-tag-
ged37 PP1α complementary DNA (cDNA) were cloned into pCMV-Tag2B vector
to generate PP1α expression plasmid. pCDNA3.1-hygro-B-Raf was purchased from
Addgene. B-Raf and PML-I cDNA were subcloned into pGEX-4T-1 vector and
used to express GST-B-Raf and GST-PML protein. All mutant constructs of B-Raf
and PP1α were generated using a QuickChange Lightning Site-Direct Mutagenesis
(Agilent Technologies) and all mutations were confirmed by sequencing. HA-Myr-
AKT1/AKT2/AKT3, HA-SGK1Δ60, HA-S6K1-CA and HA-14-3-3 isoforms have
been previously described54. The SMART pool or two independent siRNA
duplexes targeted to PML, PTEN, PP1α, PP2A-C, S6K1 and control non-target
siRNA were purchased from Dharmacon or Sigma. The sequences for the siRNA
are listed in Supplementary Table 1. The target sequences in the pLKO-PML
shRNA vector against human PML were 5′-GTGTACGCCTTCTCCATCAAA-3′
and 5′-CACCCGCAAGACCAACAACAT-3′. Tautomycin was from Enzo Life
Sciences. U0126 was from Selleck Chemicals. EGF, Lipofectamine 2000, Lipo-
fectamine RNAiMAX, RPMI, Dulbecco's modified Eagle's medium (DMEM), Opti-
MEM reduced serum media and fetal bovine serum (FBS) were from Invitrogen.
Polybrene and puromycin were from Sigma. We used the following primary
antibodies for immunoblotting: anti-p-ERK (Cell Signaling Technology, 9101,
1:1000), anti-ERK (Cell Signaling Technology, 9102, 1:1000), anti-p-MEK (Cell
Signaling Technology, 9154, 1:1000), anti-MEK (Cell Signaling Technology, 9126,
1:1000), anti-A-Raf (Cell Signaling Technology, 4432, 1:1000), anti-B-Raf (Santa
Cruz Biotechnology, sc-5284, 1:1000), anti-B-Raf (Santa Cruz Biotechnology, sc-
9002, 1:1000), anti-C-Raf (Cell Signaling Technology, 9422, 1:1000), anti-p-AKT
substrate (RXXS*/T*) (Cell Signaling Technology, 9614, 1:1000), anti-p-AKT (Cell
Signaling Technology, 9271, 1:1000), anti-AKT (Cell Signaling Technology, 9272,
1:1000), anti-p-S6K (Cell Signaling Technology, 9234, 1:1000), anti-S6K (Cell
Signaling Technology, 2708, 1:1000), anti-IRS1 (Cell Signaling Technology, 3407,
1:1000), anti-IRS2 (Cell Signaling Technology, 4502, 1:1000), anti-PP2A-C (Cell
Signaling Technology, 2259, 1:1000), anti-p-CREB (Cell Signaling Technology,
9198, 1:1000), anti-GAPDH (Cell Signaling Technology, 2118, 1:6000), anti-PML
(Bethyl Laboratories, A301-167A, 1:2000), anti-HA (Santa Cruz Biotechnology, sc-
805, 1:1000), anti-HSP90 (BD Biosciences, 610419, 1:4000, anti-PP1α (Novus
Biologicals, NB-110-57428, 1:1000), anti-Flag (Sigma-Aldrich, F1804, 1:4000), anti-
β-actin (Sigma-Aldrich, A5316, 1:4000), anti-Rb (Santa Cruz Biotechnology, sc-50,
1:1000) and anti-Lamin B1 (Abcam, ab16048, 1:1000).
Cell culture, transfection and lentivirus production. All cell lines were purchased
from the American Type Culture Collection, cultured in RPMI or DMEM sup-
plemented with 10% FBS and tested for mycoplasma contamination every month.
Transfections were performed using Lipofectamine 2000 or Lipofectamine RNAi-
MAX reagent (Invitrogen) according to the manufacturer’s instruction. In brief,
1 × 105 cells were transfected with 1 μg of DNA plasmids or 50 nM siRNA in a 6-
well dish. Cells were recovered into completed media after 12 h of transfection and
then harvested at the indicated times. For lentivirus production, human PP1α
cDNA was subcloned into the pWPI-Puro lentiviral vector to generate pWPI-Puro-
PP1α. pWPI-Puro Vector or pWPI-Puro-PP1α (6 μg), pMD2.G (1.5 μg) and
psPAX2 (4.5 μg) were co-transfected into 293T cells using Lipofectamine 2000. The
virus supernatants were collected 48 h after transfection and filtered through a 0.45
μm filter. Freshly made virus supernatants supplemented with 4 μg/ml polybrene
were added to exponentially growing LNCaP and PC3 cells. After 5 h, fresh
medium was added. CaP cells were then selected with 2 μg/ml puromycin (Sigma)
for 48 h after 2-day infection and then used for the cell migration and invasion
assay.
Immunofluorescence. Cells were grown on coverslips, fixed with 4% paraf-
ormaldehyde and permeabilized with ice-cold methanol. Cells were rinsed with
phosphate-buffered saline, blocked with 10% goat serum and then incubated with
primary antibody overnight, followed by incubation with Alexa Fluor-conjugated
secondary antibodies (Life Technologies). Coverslips were mounted with ProLong
Gold Antifade reagent with DAPI (Life Technologies). The following primary
antibodies were used for immunofluorescence: anti-Flag (Sigma-Aldrich, F1804,
1:400), anti-HA (Santa Cruz Biotechnology, sc-805, 1:400), anti-PML (Santa Cruz
Biotechnology, sc-966, 1:400) and anti-PP1α (Bethyl Laboratories, A300-904A,
1:400). The stained slides were visualized by a bright-field or confocal microscope.
Senescence-associated β-galactosidase activity in prostate tissue was measured with
the senescence detection kit (Calbiochem) on 5 μm thickness frozen section.
Western blotting and immunoprecipitation. Cell lysates or prostate tissues were
prepared in RIPA buffer (Sigma) supplemented with protease (Roche) and phos-
phatase (Sigma) inhibitor. Proteins were separated on 4–12% Bis-Tris gradient gels
(Invitrogen), transferred to polyvinylidine difluoride membranes (Immobilon P,
Millipore) and the blots were probed with the indicated antibodies. Densitometry
quantification was performed with ImageJ. Nuclear/cytoplasmic fractionation was
performed as previously described55. For immunoprecipitation, cells were lysed in
lysis buffer (50 mM Tris at pH 7.5, 10% glycerol, 5 mMMgCl2, 150 mM NaCl, 0.2%
NP-40, protease (Roche) and phosphatase (Sigma) inhibitor) and the lysates were
incubated with anti-PML (Santa Cruz Biotechnology, sc-966, 1:100) or anti-PP1α
(Invitrogen, 43-8100, 1:50) or anti-B-Raf (Santa Cruz Biotechnology, sc-5284,
1:100) or anti-Rb (Santa Cruz Biotechnology, sc-102, 1:100) or anti-Flag (Sigma-
Aldrich, F1804, 1:100) antibody overnight at 4 °C. The protein G sepharose (GE
Healthcare) was then added and incubated for another 2 h. The immunoprecipi-
tates were washed with wash buffer (50 mM Tris at pH 7.5, 5 mM MgCl2, 150 mM
NaCl, 0.1% NP-40, protease (Roche) and phosphatase (Sigma) inhibitor) three
times and eluted with 2× SDS sample buffer. Prostate tissues from WT and Ptenpc
−/−mice as well as Primary Ptenlox/lox MEFs and their transduction with retrovirus-
expressing PURO-IRES-GFP or Cre-PURO-IRES-GFP have been previously
described4. Uncropped scans for western blotting presented in main figures are
provided in Supplementary Figure 3.
In vitro kinase and phosphatase assays. In vitro kinase assays were performed as
previously described56. Briefly, bacterial-expressed GST-PP1α-H248 (the
phosphatase-dead mutant to avoid the autodephosphorylation of PP1α) or GST-B-
Raf was purified using Glutathione Sepharose 4B (GE Healthcare) according to the
manufacturer’s instructions. To determine the residue(s) on PP1α protein phos-
phorylated by S6K1, recombinant S6K1 (R&D Systems) was incubated with 1 μg of
GST-PP1α-H248. For the in vitro phosphatase assays, recombinant ERK2 (R&D
Systems) was incubated with 1 μg of GST-B-Raf in the absence or presence of PP1α
(Lifespan Bioscience) or PP2A-C (Abcam). Both reactions were incubated in kinase
assay buffer (50 mM Tris-HCl pH 7.5, 2 mM MgCl2, 0.1 mM EDTA, 2 mM DTT,
0.1 mM ATP) with 5 μCi [γ-32P] ATP. For PP1α treatment, 1 mM MnCl2 was
added to the kinase assay buffer to promote PP1α activity. The reaction was
initiated by the addition of GST-PP1α-H248 or GST-B-Raf in a volume of 30 μl for
30 min at 30 °C followed by the addition of sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) sample buffer to stop the reaction before resolved
by SDS-PAGE. To determine B-Raf kinase activity towards phosphorylating
MEK1, in vitro kinase assays were performed as described previously57. Briefly, B-
Raf kinase was immune-purified from 293T cells transfected with Flag-B-Raf
constructs. GST-MEK1 was expressed in BL21 Escherichia coli and purified using
Glutathione Sepharose 4B media (GE Healthcare). B-Raf kinase was incubated with
0.2 μg of GST-MEK1 in the absence or presence of PP1α or PP2A-C in kinase assay
buffer (10 mM HEPES pH 8.0, 10 mM MgCl2, 1 mM dithiothreitol, 0.1 mM ATP).
Reaction was initiated by the addition of GST-MEK1 in a volume of 30 μl for 15
min at 30 °C followed by the addition of SDS-PAGE sample buffer to stop the
reaction before resolved by SDS-PAGE. Nuclear PP1α phosphatase activity was
determined by in vitro phosphatase assays using CREB as the substrate as described
previously58. Phosphorylated CREB protein was immune-purified from 293T cells
transfected with Flag-CREB. The phosphatase assay was carried out using Flag-
CREB and PP1α in 1X NEBuffer for PMP supplemented with 1 mM MnCl2 (New
England Biolabs). Bacterially expressed and purified GST-PML was added as
indicated in the experiments.
Cell migration and invasion assay. CaP cells stably expressing pWPI-Vector or
pWPI-PP1α were detached into single-cell suspension. LNCaP (1 × 105) or PC3
(5 × 103 and 5 × 104 for migration and invasion assay, respectively) cells in 100 μl of
0.1% FBS-containing RPMI medium in the absence or presence of 20 μM U0126
were placed into the top chamber of 8 μm transwell inserts for migration assay or
Matrigel-coated transwell inserts for invasion assay (BD Biosciences). A volume of
600 μl of 10% FBS-containing RPMI in the absence or presence of 20 μM U0126
were added to the bottom wells. After 24 h or 48 h (for LNCaP invasion assay
only), cells on the upper surface of the inserts were removed with a cotton swab.
Migrated cells were fixed in 10% formalin, then stained with 0.2% crystal violet for
10 min. Cells were counted in four microscopic fields under ×20 magnification.
Results are representative of three independent experiments.
Array CGH analysis. The data were downloaded from GEO database (Grasso:
GSE35988) or cBioportal (for Robinson et al.9 data set) with focus on the aCGH
data sets. The R scripts were used to process the data. The cutoff threshold we used
is −0.35 to −0.8 as heterozygous deletions, those lower than −0.8 as homozygous
deletions, 0.6 to 0.8 as 1-copy gain and those higher than 0.8 as 1-copy gain.
Statistical analysis. The 2 × 2 contingency tables were constructed and were used
to analyze categorical data (for example, copy number alteration). The data sets
were compared using Fisher’s exact test. For analysis of average data, data sets were
compared using unpaired two-tailed Student’s t-tests. P-values of <0.05 were
considered to be statistically significant.
Data availability. The authors declare that the data supporting the findings of this
study are available within the article and its Supplementary Information files. All
relevant data are available from the authors upon request.
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